Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)‏ by Gail J. Roboz, Sumithra J. Mandrekar, Pinkal Desai, Kristina Laumann, Alison R. Walker, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Eyal C. Attar, Wendy Stock, Clara D. Bloomfield, Jessica Kohlschmidt, Krzysztof Mrózek, Duane C. Hassane, Levi Garraway, Judit Jané-Valbuena, Michele Baltay, Adam Tracy, Guido Marcucci, Richard M. Stone, and Richard A. Larson BloodAdv Volume 2(24):3608-3617 December 26, 2018 © 2018 by The American Society of Hematology

Gail J. Roboz et al. Blood Adv 2018;2:3608-3617 © 2018 by The American Society of Hematology

CONSORT diagram. CONSORT diagram. Gail J. Roboz et al. Blood Adv 2018;2:3608-3617 © 2018 by The American Society of Hematology

Kaplan-Meier estimate of OS by treatment arm. Kaplan-Meier estimate of OS by treatment arm. Arm A, decitabine; arm B, decitabine + bortezomib. Gail J. Roboz et al. Blood Adv 2018;2:3608-3617 © 2018 by The American Society of Hematology

Oncoprint of mutations found in all treated patients. Oncoprint of mutations found in all treated patients. Each column corresponds to an individual patient, and each row corresponds to a specific mutation, the frequency of which is indicated as a percentage on the left of the figure and as a bar graph on the right. The bar plot on the right indicates the number of mutated patients. The bar plot at the top indicates the number of mutations in each patient. Gail J. Roboz et al. Blood Adv 2018;2:3608-3617 © 2018 by The American Society of Hematology